Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43851   clinical trials with a EudraCT protocol, of which   7283   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2018-003171-35
    Sponsor's Protocol Code Number:IgPro20_3007
    National Competent Authority:Italy - Italian Medicines Agency
    Clinical Trial Type:EEA CTA
    Trial Status:Ongoing
    Date on which this record was first entered in the EudraCT database:2021-01-22
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedItaly - Italian Medicines Agency
    A.2EudraCT number2018-003171-35
    A.3Full title of the trial
    A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra®) in Adults with Dermatomyositis (DM)
    Studio per valutare l'efficacia, la sicurezza e la farmacocinetica di IgPro20 (immunoglobulina sottocutanea, Hizentra®) negli adulti con dermatomiosite (DM)
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A study to evaluate the efficacy, safety, and pharmacokinetics of IgPro20 in adults with dermatomyositis (DM)
    Studio per valutare l'efficacia, la sicurezza e la farmacocinetica di IgPro20 negli adulti con dermatomiosite (DM)
    A.3.2Name or abbreviated title of the trial where available
    NA
    NA
    A.4.1Sponsor's protocol code numberIgPro20_3007
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorCSL BEHRING GMBH
    B.1.3.4CountryUnited States
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportCSL Behring LLC, 1020 First Avenue, King of Prussia, PA 19406
    B.4.2CountryUnited States
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationCSL Behring GmbH
    B.5.2Functional name of contact pointTrial Registration Coordinator
    B.5.3 Address:
    B.5.3.1Street AddressEmil-von-Behring-Strasse 76
    B.5.3.2Town/ cityMarburg
    B.5.3.3Post code35041
    B.5.3.4CountryGermany
    B.5.4Telephone number003916108784000
    B.5.5Fax number0000000
    B.5.6E-mailclinicaltrials@cslbehring.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Hizentra
    D.2.1.1.2Name of the Marketing Authorisation holderCSL Behring Gmbh
    D.2.1.2Country which granted the Marketing AuthorisationGermany
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product namehuman immunoglobulin G
    D.3.2Product code [IgPro20]
    D.3.4Pharmaceutical form Solution for injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPSubcutaneous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNhuman immunoglobulin G
    D.3.9.2Current sponsor codeIgPro20
    D.3.9.3Other descriptive nameHizentra
    D.3.9.4EV Substance CodeSUB127300
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number200
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) Yes
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboSolution for infusion
    D.8.4Route of administration of the placeboSubcutaneous use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Dermatomyositis
    Dermatomiosite
    E.1.1.1Medical condition in easily understood language
    Dermatomyositis is an uncommon inflammatory disease marked by muscle weakness and a distinctive skin rash.
    La dermatomiosite è una malattia infiammatoria non comune caratterizzata da debolezza muscolare e una particolare eruzione cutanea.
    E.1.1.2Therapeutic area Diseases [C] - Skin and Connective Tissue Diseases [C17]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level LLT
    E.1.2Classification code 10001403
    E.1.2Term Adult dermatomyositis
    E.1.2System Organ Class 100000004858
    E.1.3Condition being studied is a rare disease Yes
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    The primary objective of this study is to assess the efficacy of IgPro20 SC doses in comparison to placebo in adult subjects with DM, as measured by responder status based on the Total Improvement Score (TIS) assessments.
    L’obiettivo primario di questo studio è valutare l’efficacia delle dosi SC di IgPro20 rispetto al placebo in soggetti adulti con DM, misurata dallo stato di rispondente in base alle valutazioni Punteggio di miglioramento totale (Total Improvement Score, TIS).
    E.2.2Secondary objectives of the trial
    The secondary objectives of the study are to assess the efficacy, with additional clinical outcome measures, of IgPro20 in comparison to placebo, the safety of IgPro20 in comparison to placebo, and the long term safety and efficacy of IgPro20
    Gli obiettivi secondari dello studio sono valutare l’efficacia, con misure dell’esito clinico aggiuntive, di IgPro20 rispetto al placebo, valutare la sicurezza di IgPro20 rispetto al placebo e valutare la sicurezza e l’efficacia a lungo termine di IgPro20.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    Male or female subjects = 18 years of age with diagnosis of at least probable (idiopathic inflammatory myopathies) IIM per EULAR/ACR Classification Criteria which includes confirmation of dermatomyositis (DM) rash/manifestation, disease activity defined by presence of DM rash / manifestation or an objective disease activity measure, and disease severity defined by Physician global visual analog scale (VAS) with a minimum value of 2.0 cm on a 10 cm scale and MMT-8 = 142 or CDASI total activity score = 14.
    Soggetti di sesso maschile o femminile = 18 anni d’età con diagnosi di IIM (miopatie infiammatorie idiopatiche) almeno probabili secondo i criteri di classificazione EULAR/ACR che include conferma di eruzione cutanea/manifestazione di dermatomiosite (DM), attività della malattia definita dalla presenza di eruzione cutanea / manifestazione di DM o una misura dell’attività della malattia obiettiva e gravità della malattia definita dalla scala analogica visiva (VAS) globale del medico con un valore minimo di 2,0 cm su una scala di 10 cm e MMT-8 = 142 o punteggio dell’attività totale CDASI = 14.
    E.4Principal exclusion criteria
    Cancer-associated myositis, evidence of active malignant disease or malignancies diagnosed within the previous 5 years, Physician Global Damage = 3, or clinically relevant improvement between Screening Visit and Baseline
    Miosite associata a cancro, evidenza di malattia maligna attiva o neoplasie diagnosticate entro i 5 anni precedenti, Danno globale fisico = 3 o miglioramento clinicamente rilevante tra la Visita di screening e il Basale.
    E.5 End points
    E.5.1Primary end point(s)
    Responder rate
    Tasso di risposta
    E.5.1.1Timepoint(s) of evaluation of this end point
    Weeks 17, 21, and 25
    Settimane 17, 21 e 25
    E.5.2Secondary end point(s)
    1. Mean Total Improvement Score (TIS),
    2. Point estimates and 95% CI for mean difference (IgPro20 – placebo) in TIS,
    3. Mean changes from Baseline in Manual Muscle Testing (MMT-8),
    4. Point estimates and 95% CI for mean change difference (IgPro20 – placebo) in MMT-8,
    5. Mean changes from Baseline in Cutaneous Dermatomyositis Disease
    Area and Severity Index (CDASI) total activity score,
    6. Point estimates and 95% CI for mean change difference (IgPro20 – placebo),
    7. Number of subjects who are able to reduce the oral corticosteroid dose by = 25% ,
    8. Percentage and 95% CI of subjects who are able to reduce the oral corticosteroid dose by = 25%
    9. Point estimates and 95% CI for the odds ratio (IgPro20:Placebo) of subjects who are able to reduce the oral corticosteroid dose by = 25%
    10. Mean TIS throughout the study,
    11. Percentage of subjects achieving TIS = 20, = 40, and = 60 points,
    12. Time to first achieving TIS = 20, = 40, and = 60 points on the TIS,
    13. Percentage of subjects achieving TIS = 20 points at the end of the study participation,
    14. Mean changes in individual CSMs except muscle enzymes and CDASI from Baseline,
    15. Mean changes in individual CSMs except muscle enzymes and CDASI from Week 25,
    16. Number of subjects meeting Definition of Worsening (DOW) at least once, twice, or > twice,
    17. Percentage of subjects meeting DOW at least once, twice, or > twice,
    18. Time to meeting DOW for the first time,
    19. Number of subjects meeting DOW and receiving rescue corticosteroid treatment,
    20. Percentage of subjects meeting DOW and receiving rescue corticosteroid treatment,
    21. Number of subjects who start oral corticosteroid dose taper,
    22. Percentage of subjects who start oral corticosteroid dose taper,
    23. Number of subjects who are able to reduce the oral corticosteroid dose by = 25%, = 50%, = 75%,
    24. Number of subjects who are able to reduce the oral corticosteroid dose by = 25%, = 50%, = 75%,
    25. Percentage of subjects who are able to reduce the oral corticosteroid dose by = 25%, = 50%, = 75%,
    26. Percentage of subjects who are able to reduce the oral corticosteroid dose by = 25%, = 50%, = 75%,
    27. Percentage of subjects receiving rescue corticosteroid treatment,
    28. Percentage of subjects whose rescue corticosteroid treatment is
    tapered,
    29. Time to first intake of rescue corticosteroid treatment,
    30. Number of subjects having at least 1 level, 2 levels, and more than 2 levels of improvement from Baseline in mobility, self-care, and usual activities domains of EQ-5D-5L,
    31. Percentage of subjects having at least 1 level, 2 levels, and more than 2 levels of improvement from Baseline in mobility, self-care, and usual activities domains of EQ-5D-5L,
    32. Number of subjects having no reduction in levels, at least 1 level, 2 levels, and more than 2 levels of improvement in mobility, self-care, and usual activities domains of EQ-5D-5L from Week 25,
    33. Percentage of subjects having no reduction in levels, at least 1 level, 2 levels, and more than 2 levels of improvement in mobility, self-care, and usual activities domains of EQ-5D-5L from Week 25,
    34. Percentage of subjects with Treatment Emergent Adverse Events (TEAEs),
    35. Percentage of subjects with related TEAEs,
    36. Percentage of subjects with serious TEAEs,
    37. Rate of TEAEs per infusion,
    38. Rate of TEAEs per infusion, by severity,
    39. Rate of related TEAEs per infusion,
    40. Rate of serious TEAEs per infusion.
    1. Punteggio di miglioramento totale medio (TIS),
    2. Stime puntuali e CI al 95% per la differenza media (IgPro20 - placebo) nel TIS,
    3. Cambiamenti medi rispetto al Basale del Test muscolare manuale (MMT-8),
    4. Stime puntuali e CI al 95% per la differenza del cambiamento medio (IgPro20 - placebo) nel MMT-8,
    5. Cambiamenti medi rispetto al Basale del punteggio di attività totale del Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI),
    6. Stime puntuali e CI al 95% per la differenza del cambiamento medio (IgPro20 - placebo),
    7. Numero di soggetti in grado di ridurre del = 25% la dose di corticosteroidi orali.
    8. Percentuale e IC al 95% dei soggetti in grado di ridurre del = 25% la dose di corticosteroidi orali
    9. Stime puntuali e IC al 95% per l’odds ratio (IgPro20:placebo) dei soggetti in grado di ridurre del = 25% la dose di corticosteroidi orali
    10. TIS medio per tutto lo studio,
    11. Percentuale di soggetti che raggiungono TIS = 20, = 40 e = 60 punti,
    12. Tempo per il raggiungimento del primo TIS = 20, = 40 e = 60 punti sul TIS,
    13. Percentuale di soggetti che raggiungono TIS = 20 punti alla fine della partecipazione allo studio,
    14. Variazione media delle singole CSM con l’eccezione degli enzimi muscolari e del CDASI rispetto al basale.
    15. Variazione media delle singole CSM con l’eccezione degli enzimi muscolari e del CDASI rispetto alla Settimana 25.
    16. Cambiamenti medi rispetto al Basale,
    17. Cambiamenti medi CSM individuali a eccezione degli enzimi muscolari dalla Settimana 25,
    18. Numero dei soggetti che soddisfano la Definizione di peggioramento (DOW) almeno una volta, due volte o > due volte,
    19. Percentuale di soggetti che soddisfano la DOW almeno una volta, due volte o > due volte,
    20. Tempo per la soddisfazione della DOW per la prima volta,
    21. Numero dei soggetti che soddisfano la DOW e ricevono un trattamento steroideo di emergenza,
    22. Percentuale di soggetti che soddisfano la DOW e ricevono un trattamento steroideo di emergenza,
    23. Numero di soggetti che iniziano a ridurre la dose di corticosteroidi orali.
    24. Percentuale dei soggetti che iniziano a ridurre la dose di corticosteroidi orali.
    25. Numero di soggetti in grado di ridurre del = 25%, = 50%, = 75%, la dose di corticosteroidi orali.
    26. Numero di soggetti in grado di ridurre del = 25%, = 50%, = 75%, la dose di corticosteroidi orali.
    27. Percentuale dei soggetti in grado di ridurre del = 25%, = 50%, = 75%, la dose di corticosteroidi orali.
    28. Percentuale dei soggetti in grado di ridurre del = 25%, = 50%, = 75%, la dose di corticosteroidi orali.
    29. Percentuale di soggetti che ricevono un trattamento steroideo di emergenza,
    30. Percentuale di soggetti il cui trattamento steroideo di emergenza viene ridotto,
    31. Numero dei soggetti che presentano almeno 1 livello, 2 livelli e oltre 2 livelli di miglioramento dal Basale nei domini mobilità, cura di sé e attività abituali dell’EQ-5D-5L,
    32. Percentuale di soggetti che presentano almeno 1 livello, 2 livelli e oltre 2 livelli di miglioramento dal Basale nei domini mobilità, cura di sé e attività abituali dell’EQ-5D-5L,
    33. Numero dei soggetti che non presentano una riduzione dei livelli, almeno 1 livello, 2 livelli e oltre 2 livelli di miglioramento nei domini mobilità, cura di sé e attività abituali dell’EQ-5D-5L dalla Settimana 25,
    34. Percentuale di soggetti che non presentano una riduzione dei livelli, almeno 1 livello, 2 livelli e oltre 2 livelli di miglioramento nei domini mobilità, cura di sé e attività abituali dell’EQ-5D-5L dalla Settimana 25,
    35. Percentuale di soggetti con Eventi avversi emergenti dal trattamento (TEAE),
    36. Percentuale di soggetti con TEAE correlati,
    37. Percentuale di soggetti con TEAE gravi,
    38. Percentuale di TEAE per infusione,
    39. Percentuale di TEAE per infusione, per gravità,
    40. Percentuale di TEAE correlati per infusione,
    41. Percentuale di TEAE gravi per infusione.
    E.5.2.1Timepoint(s) of evaluation of this end point
    1. Up to Week 25,
    2. Up to Week 25,
    3. Up to Week 25,
    4. Up to Week 25,
    5. Up to Week 25,
    6. Up to Week 25,
    7. Up to Week 25,
    8. Up to Week 25,
    9. Up to Week 25,
    10. Baseline up to Week 53,
    11. Up to Week 53,
    12. Up to Week 53,
    13. Up to Week 53,
    14. Up to Week 25,
    15. Week 25 to Week 53,
    16. Week 9 up to Week 25,
    17. Week 9 up to Week 25,
    18. Week 9 up to Week 25,
    19. Week 9 up to Week 25,
    20. Week 9 up to Week 25,
    21. Up to Week 25,
    22. Up to Week 25,
    23. Up to Week 25,
    24. Up to Week 53,
    25. Up to Week 25,
    26. Up to Week 53,
    27. Week 9 up to Week 25,
    28. Week 9 up to Week 25,
    29. Week 9 up to Week 25,
    30. Up to Week 25,
    31. Up to Week 25,
    32. Up to Week 53,
    33. Week 25 up to Week 53,
    34-40. Up to Week 56.
    1. Fin a Settimana 25, 2. Fin a Settimana 25, 3 .Fin a Settimana 25, 4. Fin a Settimana 25, 5. Fin a Settimana 25, 6. Fin a Settimana 25, 7. Fin a Settimana 25, 8. Fin a Settimana 25, 9. Fin a Settimana 25, 10. Baseline fin a Settimana 53, 11. Fin a sett. 53, 12. Fin a sett. 53, 13. Fin a sett. 53, 14. Fin a sett. 25, 15. Sett. 25 a Sett. 53, 16. Sett. 9 fin a Sett. 25, 17. Sett. 9 fin a Sett. 25, 18. Sett. 9 fin a Setti. 25,
    19. Sett. 9 fin a Sett. 25, 20. Sett. 9 fin a Sett. 25, 21. Fin a Sett. 25, 22. Fin a Sett. 25, 23. Fin a Sett. 25, 24. Fin a Sett. 53, 25. Fin a Sett. 25, 26. Fin a Sett. 53, 27. Sett. 9 fin a Sett. 25, 28. Sett. 9 fin a Sett. 25, 29. Sett. 9 fin a Sett. 25, 30. Fin a Sett. 25, 31. Fin a Sett. 25, 32. Fin a Sett. 53, 33. Sett. 25 fin a Sett. 53, 34-40. Fin a Sett. 56
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety No
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned5
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA36
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA Information not present in EudraCT
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Argentina
    Australia
    Canada
    Japan
    Mexico
    Russian Federation
    Ukraine
    United States
    Switzerland
    European Union
    United Kingdom
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    LVLS
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years3
    E.8.9.1In the Member State concerned months6
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years3
    E.8.9.2In all countries concerned by the trial months6
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 94
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 32
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state6
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 50
    F.4.2.2In the whole clinical trial 126
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    None
    Nessuno
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2019-09-27
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2019-10-21
    P. End of Trial
    P.End of Trial StatusOngoing
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Apr 20 11:42:05 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA